Understanding mRNA Vaccines: Revolutionizing Medicine

mRNA vaccines have recently become a revolutionary approach in modern medicine which is part of the COVID-19 vaccines by Pfizer-BioNTech and Moderna. These vaccines are based on the participation of the so-called messenger RNA (mRNA), which teaches the cells of the body to produce a certain protein that initiates an immune response.

Mechanism: What is important here is that mRNA vaccines are not live virus vaccines. They in fact only release synthetic mRNA into cells and these cells go on to create the spike protein of the virus. This protein stimulates the immune system to produce what is called antibodies.

Advantages: The mRNA vaccines can be made faster and can be easily adapted. They have also manifested high levels of effectiveness and safety, so they can be regarded as a rather promising direction in the further creation of vaccines for various diseases.

Challenges: Concerns of stability and storage is well known challenge because in the case of some products they need to be stored at ultra-cold temperatures. Current research studies focus on these issues to improve accessibility among the population of interest.

Future Implications: Besides the case of the infectious diseases, the mRNA technology can be used to treat cancer and genetic diseases as well as other diseases. This shows that it is flexible yet very effective, and therefore marks an evolution in the way that disease can be addressed and treated.

Conclusion: mRNA-based vaccines offer several advantages such as versatility, and capacity for forming a very swift response team. More development and funding of this technology are important to future medical strategies.

Author: Mia Calloway

References: Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261-279. doi:10.1038/nrd.2017.243.

Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014 Oct;13(10):759-780. doi:10.1038/nrd4278.

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi:10.1056/NEJMoa2034577.

Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2—Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi:10.1056/NEJMoa2022483.